文献速递白血病淋巴瘤

靶向BCL-XL的新型CD7抗体药物偶联物在T-ALL中显示强效抗白血病活性

A novel CD7-directed antibody-drug conjugate targeting BCL-XL with potent anti-leukemic activity in T-cell acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2026-06-08

T-ALL现有强化疗方案儿童总生存率约85%、成人不足50%,亟需新疗法。BCL-XL抑制剂因靶向性血小板减少受限。研究设计携带BCL-XL选择性抑制剂的抗hCD7单抗ADC(ADC-CD7-BCL-XLi),可高效杀伤多数T-ALL细胞系,在PDX中具强抗白血病活性且对血小板无毒性,与venetoclax协同延长缓解和生存,联合化疗可达治愈。

要点

  • ADC-CD7-BCL-XLi可高效杀伤多数T-ALL细胞系并在PDX中显示强抗白血病活性。
  • 该ADC对血小板无毒性,规避了BCL-XL抑制剂的血小板减少局限。
  • 与venetoclax协同延长白血病缓解和鼠生存,联合化疗可达治愈。

核心结论

  • ADC-CD7-BCL-XLi在T-ALL临床前模型中具强效抗白血病活性且不损伤血小板,支持其进入T-ALL患者评估。

研究设计与样本

  • 临床前研究:设计抗hCD7单抗携带BCL-XL选择性抑制剂的ADC,并在T-ALL细胞系及PDX中评价。

主要发现

  • ADC-CD7-BCL-XLi高效杀伤多数T-ALL细胞系。
  • 在T-ALL PDX中ADC-CD7-BCL-XLi显示强抗白血病活性且对血小板无毒性。
  • ADC-CD7-BCL-XLi与venetoclax协同延长白血病缓解和鼠生存。
  • ADC-CD7-BCL-XLi联合venetoclax再联合化疗可达治愈。

关键数值与推荐

  • 现有强化疗下T-ALL总生存率儿童约85%、成人不足50%。

临床怎么用

  • ADC-CD7-BCL-XLi可作为T-ALL潜在桥接造血干细胞移植(HSCT)的选项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current treatments of T-cell acute lymphoblastic leukemia (T-ALL) are based on intensive chemotherapy regimens which provide overall survival rates of ~85% in children and <50% in adults. Therefore, there is an unmet need for novel therapeutic options in T-ALL. Pre-clinical studies and clinical trials have demonstrated that inhibitors of BCL-XL and/or BCL-2, two anti-apoptotic proteins of the BCL-2 family, are anti-leukemic in T-ALL. However, BCL-XL inhibitors (BCL-XLi) efficacy is undermined by severe, on-target thrombocytopenia. We report here the design of a novel anti-hCD7 mAb-based ADC carrying a BCL-XL-selective inhibitor (ADC-CD7-BCL-XLi) that circumvents this significant limitation. We show that ADC-CD7-BCL-XLi efficiently kills most T-ALL cell lines. Using T-ALL PDXs we further show that (i) ADC-CD7-BCL-XLi displays potent anti-leukemic activity and is devoid of toxicity to platelets; (ii) ADC-CD7-BCL-XLi acts synergistically with venetoclax, a BCL-2 selective antagonist, to prolong leukemia remission and mouse survival; (iii) the anti-leukemic effect of the ADC-CD7-BCL-XLi+venetoclax combination can lead to cure when combined with chemotherapy. These pre-clinical data strongly support the evaluation of ADC-CD7-BCL-XLi in T-ALL patients, including as a potential bridging option to curative hematopoietic stem cell transplantation (HSCT).

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Oliveira ML, Nuantang K, Huré G, et al. A novel CD7-directed antibody-drug conjugate targeting BCL-XL with potent anti-leukemic activity in T-cell acute lymphoblastic leukemia. Leukemia. 2026. PMID: 42260111. doi:10.1038/s41375-026-02998-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。